Podcast “ImmunVERMITTELT”: Prof. Philipp Beckhove gives insights into tumor immunology
16.01.2025Prof. Philipp Beckhove, Scientific Director of the LIT, was guest in the podcast “ImmunVERMITTELT” by Janssen-Cilag GmbH.
Author: Kerstin Wild
High-profile LIT publication sparks global discussion
10.01.2025Recent work by LIT scientists Prof. Luca Gattinoni and Dr. Jeremy Baldwin published in Cell has generated significant interest both inside and outside the cancer immunology field.
Four LIT scientists among Stanford’s top 2% of scientists worldwide
01.10.2024LIT scientists Prof. Hinrich Abken, Prof. Markus Feuerer, Prof. Luca Gattinoni and Prof. Michael Rehli are featured in the prestigious Stanford ranking of the world’s top 2% of scientists.
LIT Retreat 2024
26.09.2024The LIT Retreat took place on September 16 and 17, 2024 at Schloss Hirschberg.
Best Abstract Award for LIT Scientist Gabriele Inchingolo
20.09.2024Gabriele Inchingolo was honored as one of the Best Abstract Awardees at the 3rd Translational Research Conference “IMMUNE & CELLULAR THERAPIES: Focus on Advanced Gene-Engineered Immune Cells” September 13-15, 2024 in Malahide (Dublin), Ireland.
Mitochondria on the move: Leveraging intercellular mitochondria transfer to boost cancer immunotherapies
13.09.2024An international team of researchers, led by Professor Luca Gattinoni at the Leibniz Institute for Immunotherapy (LIT), has developed an innovative mitochondrial transfer platform to supercharge CD8+ T cells, enabling them to overcome exhaustion and more effectively fight tumor cells.
Prof. Philipp Beckhove in Podcast “Tonspur Wissen”: When will cancer be defeated?
12.09.2024Prof. Philipp Beckhove, Scientific Director of the LIT, was guest in the podcast “Tonspur Wissen” by Leibniz Association and Rheinische Post. He talked with journalist Ursula Weidenfeld about new developments in fighting cancer with immunotherapy (in German).
Mutations in the STAG2 Protein and the Associated Spatial Alteration of DNA Structure Can Cause Leukemia
13.08.2024Researchers at the Leibniz Institute for Immunotherapy (LIT) studied hundreds of patients with acute myeloid leukemia (AML). They discovered that specific mutations in the STAG2 protein cause altered DNA folding in the cell nucleus, thereby contributing to the development of AML.
Unmasking Hidden Potential: LMO4 Enhances T Cell Cancer-Fighting Abilities
09.08.2024Researchers at the Leibniz Institute for Immunotherapy (LIT), University Hospital Regensburg (UKR) and the National Heart, Lung, and Blood Institute (NHLBI) have engineered CD8+ T cells to artificially express the gene LMO4, thereby enhancing their effectiveness against tumors.
‘Jumping Genes’ Support Immune Cells in Tissue
23.07.2024Researchers at the Leibniz Institute for Immunotherapy (LIT) describe a new type of regulation of immune cells by so-called ‘jumping genes.’
